Higher red meat consumption is associated with increased risk of all-cause, cardiovascular, and cancer mortality

Etiquetas de revisión

Datos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.

Cómo se estudió

Diseño

Estudio de cohortes (clasificado por nuestro filtro de IA)

Estudiado en

Personas

Resultado principal

Marcadores de salud y funcionamiento

Consumo medido con

No se indica

Quién lo pagó

Financiación

Financiación no declarada

Publicación

Publicado

2012-07-13 · Evid Based Nurs · vol. 15 · número 4 · págs. 121–122

Editorial

BMJ

Citado

4 citas · más que el 69% de estudios similares · 0.3× el promedio de su campo

Referencias

4 trabajos

Acceso

De pago

Áreas de investigación

Nutritional Studies and Diet · Advanced Chemical Sensor Technologies · Biochemical Analysis and Sensing Techniques

Palabras clave

Medicine, Red meat, Processed meat, Cancer, Consumption (sociology), Cause of death, Environmental health, Internal medicine, Biology, Food science, Disease, Pathology

1 autor

• Amanda Jane Cross🇺🇸 · autor de correspondenciaNational Cancer Institute

Texto inicial

El texto original del estudio, en el idioma en que se publicó.

Este estudio se publicó sin resumen, como suele pasar con las cartas de investigación y los reportes breves. Así empieza.

Abstract Background Understanding and measuring the individual level of immune protection and its persistence at both humoral and cellular levels after SARS-CoV-2 vaccination is mandatory for the management of the vaccination booster campaign. Our prospective study was designed to assess the immunogenicity of the BNT162b2 mRNA vaccine in triggering the humoral and the cellular immune response in healthcare workers up to 6 months after two doses vaccination. Methods This prospective study enrolled 208 healthcare workers from the Liège University Hospital (CHU) of Liège in Belgium. All participants received two doses of BioNTech/Pfizer COVID-19 vaccine (BNT162b2). Fifty participants were SARS-CoV-2 experienced (self-reported SARS-CoV-2 infection) and 158 were naïve (no reported SARS-CoV-2 infection) before the vaccination. Blood sampling was performed at the day of the first (T0) and second (T1) vaccine doses administration, then at 2 weeks (T2), 4 weeks (T3) and 6 months (T4) after the 1st vaccine dose administration. A total of 1024 blood samples were collected. All samples were tested for the presence of anti-Spike antibodies using DiaSorin LIAISON SARS-CoV-2 TrimericS IgG assay. Neutralizing antibodies against the SARS-CoV-2 Wuhan-like variant strain were quantified in all samples using a Vero E6 cell-based neutralization-based assay. Cell-mediated immune response was evaluated at T4 on 80 participants by measuring the secretion of IFN-γ on peripheral blood lymphocytes using the QuantiFERON Human IFN-γ SARS-CoV-2, Qiagen. All participants were monitored on weekly-basis for the novo SARS-COV-2 infection for 4 weeks after the 1st vaccine dose administration. We analyzed separately the naïve and experienced participants. Findings We found that anti-spike antibodies and neutralization capacity levels were significantly higher in SARS-CoV-2 experienced healthcare workers (HCWs) compared to naïve HCWs at all time points analyzed. Cellular immune response was similar in the two groups six months following 2nd dose of the vaccine. Reassuringly, most participants had a detectable cellular immune response to SARS-CoV-2 six months after vaccination. Besides the impact of SARS-CoV-2 infection history on immune response to BNT162b2 mRNA vaccine, we observed a significant negative correlation between age and persistence of humoral response. Cellular immune response was, however, not significantly correlated to age, although a trend towards a negative impact of age was observed. Conclusions Our data strengthen previous findings demonstrating that immunization through vaccination combined with natural infection is better than 2 vaccine doses immunization or natural infection alone. It may have implications for personalizing mRNA vaccination regimens used to prevent severe COVID-19 and reduce the impact of the pandemic on the healthcare system. More specifically, it may help prioritizing vaccination, including for the deployment of booster doses.

Texto vía OpenAlex. Los derechos de autor siguen siendo de los autores o la editorial.

Confianza de la comunidad

Cargando…

¿Cuánto confías en los hallazgos de este estudio?

Comentarios

¿Algo está mal aquí?

Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.